Sort
15,273 grants matching “antimicrobial resistance”
Randomized Intervention for Vesicoureteral Reflux (RIVUR)
$959,040Myra A. Carpenter · Univ Of North Carolina Chapel Hill · U01 · FY2010 · DK
Component 2, pp. 145-169
$958,564Gerhard Wagner · Harvard Medical School · P01 · FY2016 · GM
Component 2, pp. 145-169
$958,564Gerhard Wagner · Harvard Medical School · P01 · FY2015 · GM
Component 2, pp. 145-169
$958,564Gerhard Wagner · Harvard Medical School · P01 · FY2014 · GM
Component 2, pp. 145-169
$958,561Gerhard Wagner · Harvard Medical School · P01 · FY2017 · GM
Bacterial Functions Involved in Cell Growth Control
$956,299Susan Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Integrated Comprehensive Droplet Digital Detection (IC 3D) system for rapid detection of bacteria andantimicrobial resistance
$955,672Weian Zhao · University Of California-Irvine · R01 · FY2017 · AI
Identification of novel MDR antimicrobials from symbioses between terrestrial and marine invertebrates and rare microbial taxa
$955,138Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2021 · AI
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2014 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2013 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2015 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2017 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2016 · DE
Pathogenic differences between Cryptococcus neoformans and C. gattii
$954,819Kyung Kwon-Chung · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media
$953,094Alejandro Hoberman · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · DC
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae
$952,958Terry Roemer · Prokaryotics, Inc. · R44 · FY2019 · AI
In vivo Core
$951,755David R Andes · University Of Wisconsin-Madison · U19 · FY2021 · AI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
$950,616David B. Weiner · Wistar Institute · R01 · FY2021 · AI
Collaborative Research: URoL:ASC: Using the Rules of Antibiotic Resistance Development to Inform Wastewater Mitigation Strategies
$949,997Adina Howe · Iowa State University · · FY2023 · BIO
Novel polymeric materials with improved durability in the oral environment: tailoring responses to host and bacterial enzymes with anti-proteolytic and ecology-based antimicrobial approaches.
$949,845Carmem S. Pfeifer · Oregon Health & Science University · R35 · FY2022 · DE
Task 11: Interventional Agent Development Services Program
$949,290Jon Mirsalis · Sri International · N01 · FY2017 · AI
CAREER: Molecular evolution of antibiotic export by the SMR family of membrane proteins
$948,271Randy Stockbridge · Regents Of The University Of Michigan - Ann Arbor · · FY2019 · BIO
Integrated Comprehensive Droplet Digital Detection (IC 3D) system for rapid detection of bacteria andantimicrobial resistance
$947,235Weian Zhao · University Of California-Irvine · R01 · FY2018 · AI
Innate, Transcriptomic, and Microbiomic correlates of TB infection
$946,851Michael Haggai Glickman · Weill Medical Coll Of Cornell Univ · U19 · FY2017 · AI
Identifying novel anti-infectives by high through-put screening in whole animals
$946,258Frederick M Ausubel · Massachusetts General Hospital · R01 · FY2013 · AI